AstraZeneca, HealthCore Launch Outcomes Data Project, Seek Multi-Stakeholder Consortium
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca and HealthCore, WellPoint's clinical outcomes research unit, have begun an evidence-development partnership that will focus on "real world" outcomes data in chronic ailments such as diabetes, cardiovascular disease and dyslipidemia.
You may also be interested in...
Anthem Adds Lilly To Its Real-World Drug Outcomes Research Collaborations
The firms are still working to determine specific drugs or disease states to be studied under a five-year agreement. Speeding research dissemination may also be addressed.
Lilly-Humana Outcomes Research Partnership Has Initial Focus on Diabetes
The research will cover the impact of interventions on outcomes, adherence programs, disease management and pharmacoeconomics.
HealthCore And AstraZeneca Big Data Initiative Pushes Ahead, But Will Lack of Trust Deter Additional Partners?
AstraZeneca and HealthCore, a subsidiary of Wellpoint, are halfway through a four-year agreement to study the effectiveness and economics of marketed drugs using real world evidence. The collaboration is making progress, but reaching some goals has been a challenge, says HealthCore CEO Marcus Wilson